Management of Relapsed Multiple Myeloma after Autologous Stem Cell Transplant
Open Access
- 1 May 2015
- journal article
- case report
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 21 (5) , 793-798
Abstract
No abstract availableKeywords
Funding Information
- Onyx
- Novartis
- Celgene
- Millennium
This publication has 35 references indexed in Scilit:
- Autologous Transplantation and Maintenance Therapy in Multiple MyelomaNew England Journal of Medicine, 2014
- Second auto-SCT for treatment of relapsed multiple myelomaBone Marrow Transplantation, 2012
- Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 TrialJournal of Clinical Oncology, 2012
- Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients’ monitoring after transplantationBone Marrow Transplantation, 2012
- Clonal competition with alternating dominance in multiple myelomaBlood, 2012
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2012
- Lenalidomide after Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2012
- The genetic architecture of multiple myelomaNature Reviews Cancer, 2012
- Allogeneic Stem Cell Transplantation in Multiple Myeloma Relapsed after Autograft: A Multicenter Retrospective Study Based on Donor AvailabilityTransplantation and Cellular Therapy, 2012
- Second auto-SCT is safe and effective salvage therapy for relapsed multiple myelomaBone Marrow Transplantation, 2008